<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by M.O.R. Youkee on Medium]]></title>
        <description><![CDATA[Stories by M.O.R. Youkee on Medium]]></description>
        <link>https://medium.com/@matyoukee?source=rss-9601dc066086------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*ap9h1yVekBlH7UBwNr7akQ.jpeg</url>
            <title>Stories by M.O.R. Youkee on Medium</title>
            <link>https://medium.com/@matyoukee?source=rss-9601dc066086------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Tue, 17 Nov 2026 11:31:56 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@matyoukee/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Polka]]></title>
            <link>https://medium.com/@matyoukee/polka-45d28b19ce47?source=rss-9601dc066086------2</link>
            <guid isPermaLink="false">https://medium.com/p/45d28b19ce47</guid>
            <category><![CDATA[short-story]]></category>
            <category><![CDATA[fiction]]></category>
            <category><![CDATA[travel]]></category>
            <category><![CDATA[paraguay]]></category>
            <dc:creator><![CDATA[M.O.R. Youkee]]></dc:creator>
            <pubDate>Mon, 04 Jul 2016 19:13:58 GMT</pubDate>
            <atom:updated>2016-07-14T18:43:56.175Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*F_n1-GwA-NEkSgrYObdeCQ.jpeg" /></figure><p>I dropped off Santi on a bleak corner in a Paraguayan town well-endowed in hardware stores and animal feed suppliers but without a single restaurant. He zipped up his Canon Rebel awkwardly inside his black waterproof and I left him there, squinting and sniffing in the rain. He looked anxious.</p><p>The morning had been spent chasing stories in the carcasses of old railway stations. In the suburbs of Asuncion we had met people anxious to tell us about the history of the old rail line and to show us how they lived in the crumbling old station buildings. But as we had driven further from the capital the towns had become more desolate, the people sadder.</p><p>I took out my phone and thumbed my destination into Google maps. The suggested route, quicker by 20 minutes, involved backtracking and taking one of the country’s few asphalted roads. It would have taken me away from the old rail track that I had determined to follow, however, and I turned the rental car onto the older road, its cobblestones cemented with the rich red earth of the Paraguayan countryside.</p><p>The weather worsened and the sky descended until the points of distant Urunday trees scratched the swollen cloud belies. The road through the savannah pointed straight ahead towards an anaemic horizon. I passed a cemetery that looked like a shrunken colonial city, the doorways to the coloured tombs slightly too low, the paths between them too narrow. From there, for a 100km I didn’t see another soul.</p><p>From the passenger seat, where I had dropped my phone, a dead female voice implored me to take the next right. Take the next right. There was no right. I reached for the phone and switched it off without taking my eyes from the road. I turned on the radio. The needle swam in the fuzz. It did laps of the FM band, increasingly desperate for something to grasp on to. Then the sound of a harp. Then the guttural, alien voice of a man singing in Guarani. A Paraguayan polka. It could have been about a lover, it could have been about a murder.</p><p>Alongside the rusted tracks were the remains of 19th century buildings, their elaborate facades still evident but the rest rotting from the inside out. The roofs had caved in and the walls were mottled green, infected by a creeping moss. There were also concrete houses, but they were still with no televisions blaring, no dogs barking. Paraguayans are notorious for abandoning plans at the first sign of rain. Today it felt like an existential cancellation.</p><p>I rolled up the sleeves on the sweater I had bought in Asuncion, the only warm clothing I had. Everyone had told me I would face an infernal heat in Paraguay. I thought about my lack of preparation. I realized I had no water in the car and no way to charge my phone. I tried to remember if I had seen a spare tyre in the trunk.</p><p>Then, like wading naked into a grey sea, I went deeper. My thoughts turned to the mistakes I had made in recent months, the regrets of the last decade and to an ache that preceded my recollection. I looked down at the dashboard and my concerns turned from the suspension to my sanity. I pushed down on the accelerator until the wheels hummed over the cobble stones. Alone with the grey, the grass and the polka.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=45d28b19ce47" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How Colombia’s Drugs Battle With Novartis Could Change Healthcare in Latin America]]></title>
            <link>https://medium.com/@matyoukee/how-colombias-drugs-battle-with-novartis-could-change-healthcare-in-latin-america-fab955b392c?source=rss-9601dc066086------2</link>
            <guid isPermaLink="false">https://medium.com/p/fab955b392c</guid>
            <category><![CDATA[colombia]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[pharmaceutical]]></category>
            <dc:creator><![CDATA[M.O.R. Youkee]]></dc:creator>
            <pubDate>Sun, 05 Jun 2016 00:55:08 GMT</pubDate>
            <atom:updated>2016-06-05T00:55:08.968Z</atom:updated>
            <content:encoded><![CDATA[<p>(Originally published by <em>Americas Quarterly</em>)</p><p>An ambitious healthcare reform in Colombia may be facing its toughest challenge yet: the pharmaceutical industry.</p><p>In a bold step with wide repercussions for Latin America’s healthcare sector and drug patent law, Colombia’s Ministry of Health in late April moved to unilaterally end Swiss drug giant Novartis’ patent on the expensive cancer treatment Glivec after the company refused to sell it at lower cost. This would be the country’s first-ever “compulsory license,” which is when a government allows generic drug production without consent from the patent owner.</p><p>The move could <a href="https://www.statnews.com/pharmalot/2016/05/02/novartis-cancer-colombia-patent/">reportedly</a> save Colombia <a href="http://www.semana.com/opinion/articulo/german-manga-minsalud-enfrenta-laboratorios-farmaceuticos/467138">tens of millions of dollars</a> annually at a time when the government is struggling to rein in the ballooning costs of expanded healthcare coverage. Perhaps more concerning to the pharmaceutical industry, it could also open the door to further disputes between Latin American governments and drug companies over access to high-cost medicines.</p><p>“The Colombian healthcare system is unique and in many ways ahead of most other countries in the region,” Jaime Arias, executive director of the Colombian Association of Medical Companies (ACEMI), told <em>AQ</em>. “What happens here will have an impact on policymaking in the region.”</p><p>A spokesperson for Novartis told <em>AQ</em> that it is working with the Health Ministry “to find a mutually beneficial solution” to the dispute, which now lies with Colombia’s superintendent for industry and commerce. The spokesperson added that compulsory licenses should not be used in a threatening manner to force down prices, which “would create a damaging precedent that could apply to all patent-covered innovations.”</p><p>The standoff has been brewing for months. In a sense, it can be traced back to President Manuel Santos’ signing in February 2015 of the new <a href="https://www.minsalud.gov.co/Paginas/Con-sancion-de-Ley-Estatutaria,-la-salud-se-consolida-como-derecho-fundamental-en-Colombia.aspx">Statutory Health Law</a>, which defined healthcare as a fundamental right for all Colombians. Patients became entitled to any drug or treatment licensed in Colombia, doctors were given total freedom of prescription, and hospitals could no longer refuse to treat anyone lacking insurance papers.</p><p>Who will pay for that expanded coverage is another question — and is the key factor behind the Health Ministry’s request now for a compulsory license for Glivec (spelled Gleevec in the United States and Canada). Expanded drug coverage has placed a huge financial strain on the healthcare industry, which had accumulated debts of more than $4 billion by the end of 2015, according to data from ACEMI. The Ministry of Health, in its worst-case-scenario, projects the February 2015 law to stick an<a href="http://www.med-informatica.net/BIS/BisBcm15de2016_04a10abr16.htm"> additional $700 million on its annual pharmaceutical bill</a>. But that may be optimistic, according to Oscar Andia, vice president for pharmaceutical policy for the Colombian Medical Federation.</p><p>“The ministry has simply pulled these figures out of a hat,” Andia told <em>AQ</em>. “If patients are given unrestricted access to high cost drugs the total bill will be a lot higher than the government anticipates.”</p><p>That’s unless drug prices also come down, as Health Minister Alejandro Gaviria is attempting to make happen. His move to issue a compulsory license represents a 180-degree turn from the previous administration’s open market policies that led to what Andia calls “an orgy of profit for the pharmaceutical industry.” In 2012, the price of Rituximab, a leukemia drug, was found to be 12 times more expensive in Colombia than in the United Kingdom. Interferon beta-1b, used in the treatment of multiple sclerosis, was listed at prices <a href="http://www.elespectador.com/noticias/actualidad/vivir/medicamentos-biotecnologicos-batalla-de-los-us-1000-mil-articulo-324712">32 times higher</a> than in the EU.</p><p>To tackle spiraling costs, the Health Ministry in September 2013 introduced a new price controls policy requiring drug prices to fall into the 25th percentile based on international price referencing of comparable countries. The measure was introduced for <a href="https://www.minsalud.gov.co/Paginas/fija-precio-189-medicamentos.aspx">189 key drugs</a> and is <a href="http://www.dinero.com/pais/articulo/control-precios-medicamentos/204881">continuously expanding</a>. Cost controls have been matched with <a href="http://colombiareports.com/experts-claim-new-drug-decree-allow-potentially-dangerous-medicines-colombia/">legislation</a> regarding biosimilars drugs, which are cheap like generic drugs, but created through a different process of protein engineering.</p><p>When it came to Novartis, Gaviria first proposed the firm halve the cost of Glivec (also referred to as imatinib) to 140 pesos per milligram — the price offered by generic competitors operating in the country until 2012, when Novartis’ patent was approved. Novartis <a href="http://caracol.com.co/radio/2016/04/21/salud/1461275554_063542.html">rejected the offer on April 20</a>, and on April 26 the Health Ministry announced its intention to request the compulsory license.</p><p>The World Trade Organization allows a country to cite a health emergency as reason for issuing a compulsory license, as Brazil and India did to bring down the cost of AIDS treatments in the mid-2000s. But it is unclear if this condition is met by the need of Glivec to treat chronic myelogenous leukemia (CML), a cancer of white blood cells affecting <a href="http://www.eltiempo.com/colombia/otras-ciudades/en-colombia-hay-2836-personas-con-leucemia-mieloide-cronica/16383880">about 3,000</a> Colombians.</p><p>“In terms of number of patients, it is hard to say that CML represents a healthcare emergency in Colombia,” said Arias of ACEMI. “However, it could be argued that the high cost of treatment of CML and other diseases places a financial burden on the system that represents a health emergency.”</p><p>Approval of the compulsory license from Colombia’s superintendent of industry and commerce was initially considered a matter of protocol, as Gaviria has received strong cabinet support for his wider health reform. But opposition is reportedly coming from both the superintendent and the trade minister, who fear the license could provoke Novartis to litigate for breach of intellectual property clauses in Colombia’s free trade agreement with Switzerland. Colombia was already hit in March with multibillion-dollar lawsuits from two Canadian-owned <a href="http://www.newswire.ca/news-releases/eco-oro-minerals-notifies-colombian-government-of-investment-dispute-571277901.html">mining</a> <a href="http://www.law360.com/articles/774026/atty-behind-16-5b-colombia-gold-fight-says-more-coming">firms</a> under investment protection clauses contained in the free trade pact with Canada.</p><p>It is unknown when a decision might be made, but there is <a href="http://www.reuters.com/article/us-novartis-colombia-cancer-idUSKCN0Y9238">still time</a> for Novartis and the ministry to reach agreement on a price for Glivec and avoid a lengthy and costly legal process that neither side wants. No matter the result, Colombia’s threat to issue a compulsory license has the potential to embolden other Latin American nations to consider doing the same, especially if the progressive healthcare reform continues to gain traction as a regional model.</p><p>“The dispute shows that Latin American ministries of health can take actions to make the pharmaceutical industry think twice about high prices,” said Claudia Vaca, a former adviser in Colombia’s Health Ministry. “Whatever the outcome, the debate will draw attention to the issue of drug prices and the content of intellectual property legislation, including its flexibilities, in trade agreements.”</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=fab955b392c" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>